PCSK9抑制剂-依洛尤单抗对急性冠状动脉综合征患者血脂谱及血管内皮功能的影响

Effects of PCSK9 Inhibitor-Evolocumab on Blood Lipid Profiles and Vascular Endothelial Function in Patients with Acute Coronary Syndrome

目的:探讨PCSK9抑制剂-依洛尤单抗对急性冠状动脉综合征(ACS)患者血脂谱及血管内皮功能的影响。方法:选取2019年6月至2020年6月本院160例ACS患者,通过随机数字表法简单随机分为观察组与对照组,每组各80例,对照组给予口服阿托伐他汀,观察组在对照组的基础上给予皮下注射依洛尤单抗,比较两组患者血脂谱水平、血管内皮功能、炎症因子、不良反应情况。结果:观察组治疗后胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)较治疗前降低值大于对照组(P<0.05);观察组治疗后血清内皮素1(ET-1)、一氧化氮(NO)水平较治疗前降低值和升高值分别大于对照组(P<0.05);观察组血清炎症因子肿瘤坏死因子α(TNF-α)、白细胞介素6(IL-6)、超敏C反应蛋白(hs-CRP)水平较治疗前降低值大于对照组(P<0.05);两组不良反应发生率比较(P>0.05)。结论:PCSK9抑制剂-依洛尤单抗可有效调节ACS患者血脂水平,改善患者血管内皮功能,抑制炎症反应,用药安全性较高。

Objective:To explore the effects of proprotein convertase subtilisin/kexin type 9(PCSK9)inhibitor-evolocumab on blood lipid profiles and vascular endothelial function in patients with acute coronary syndrome(ACS).Methods:A total of 160 ACS patients in the hospital from June 2019 to June 2020 were enrolled and divided into observation group and control group by random number table method,80 cases in each group.The control group was given oral atorvastatin,while observation group was given subcutaneous injection of evolocumab on basis of control group.The levels of blood lipid profiles,vascular endothelial function,inflammatory factors and adverse reactions were compared between the two groups.Results:The difference values of cholesterol(TC),triglyceride(TG)and low-density lipoprotein cholesterol(LDL-C)before and after treatment in observation group were greater than those in control group(P<0.05),and difference values of serum endothelin 1(ET-1)and nitric oxide(NO)before and after treatment were greater than those in control group(P<0.05).The difference values of serum inflammatory factors such as tumor necrosis factorα(TNF-α),interleukin 6(IL-6)and high-sensitivity C-reactive protein(hs-CRP)before and after treatment in observation group were greater than those in control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:PCSK9 inhibitor-evolocumab can effectively regulate blood lipid level of ACS patients,improve vascular endothelial function and inhibit inflammation reactions,with high medication safety.